🔴 Safety Alert
The U.S. Food and Drug Administration (FDA) has issued a safety alert regarding reprocessed electrophysiology and ultrasound catheters manufactured by Medline Industries, citing the potential presence of residual particulates that could lead to serious patient harm. The contamination risk applies to multiple reprocessed catheter models used in cardiac and vascular procedures across U.S. hospitals and healthcare facilities.
Key takeaways
- Medline Industries is recalling certain reprocessed electrophysiology and ultrasound catheters due to potential residual particulate contamination
- Residual particles in reprocessed catheters may cause infection, thrombosis, or pulmonary embolism in patients
- The FDA advises hospitals to immediately identify affected inventory and quarantine products pending return instructions
- Healthcare facilities should verify device serial numbers against Medline’s recall list and review patient records for potential adverse events
Residual Contamination in Reprocessed Devices
According to the FDA’s safety alert, the recalled reprocessed catheters may contain residual particulates from the manufacturing or reprocessing steps. Reprocessed medical devices—those cleaned, sterilized, and repackaged for reuse—are subject to strict quality control standards, yet contamination can occur if reprocessing procedures are compromised or validation steps incomplete.
The presence of particulate matter in catheters poses direct risks during intravascular procedures. When catheters are advanced through the vascular system, loose particles can detach and lodge downstream, potentially occluding blood vessels or triggering thrombotic events. Read more about quality and safety protocols for medical devices.
Potential Clinical Outcomes of Particulate Catheter Contamination
Serious adverse events documented in catheter recalls, FDA medical device database
Source: FDA Medical Device Adverse Event Reporting System (MAERS) aggregated catheter recall analysis | GMJ News
FDA Recommendations for Hospital Response
The FDA’s recall management guidance requires hospitals to immediately cease use of affected catheter batches and implement a thorough inventory audit. Healthcare administrators should cross-reference serial numbers and lot codes against Medline’s official recall notice to identify all affected stock within their supply chain.
Institutions with documented use of recalled catheters in recent procedures are advised to conduct medical record reviews to identify potentially affected patients. Clinicians should be alerted to monitor these patients for signs of thrombosis, infection, or embolic complications, which may emerge days to weeks after catheter insertion. For clinical guidance on quality assurance in device reprocessing, see Clinical Updates from GMJ News.
Residual particulates in reprocessed catheters present a direct risk of infection, thrombosis, and pulmonary embolism in patients undergoing cardiac and vascular procedures.
— U.S. Food and Drug Administration (FDA Medical Device Safety Alert, 2024)
Broader Implications for Reprocessed Device Oversight
This recall highlights ongoing challenges in the reprocessing industry, where third-party facilities and original manufacturers must maintain alignment on cleaning validation, sterilization protocols, and quality assurance. The FDA maintains regulatory authority over reprocessed device manufacturers, requiring adherence to FDA manufacturing standards, yet variability in execution across facilities has led to multiple catheter recalls in recent years.
Hospitals should ensure their supply chain includes direct communication channels with reprocessor facilities and maintain documentation of device traceability. This recall reinforces the importance of robust quality oversight and the need for healthcare systems to balance cost considerations with rigorous validation of reprocessed device safety.
What this means
Frequently asked questions
How do I know if my hospital used these recalled catheters?
Contact your hospital’s materials management or clinical engineering department and ask them to cross-reference your institution’s purchase history and current inventory against Medline’s official recall notice. The recall affects specific lot numbers and serial ranges—your facility should have access to this data in their supply chain system.
What symptoms should I watch for if I had a procedure with one of these catheters?
Seek medical attention if you experience chest pain, shortness of breath, sudden leg swelling, fever, or signs of infection at the catheter insertion site. While many patients experience no complications, the potential risks of thrombosis and embolism can develop within days to weeks after the procedure, so awareness is important.
Are all reprocessed catheters unsafe?
No. Reprocessed medical devices are FDA-regulated and generally safe when manufactured according to strict standards. This recall affects specific Medline catheter models due to a manufacturing or validation failure in their reprocessing process. Other reprocessed devices from compliant manufacturers continue to be a safe and cost-effective option for healthcare systems.
The FDA maintains an active surveillance system for medical device recalls, and hospitals should establish protocols to respond rapidly to such alerts. Medline Industries will provide return shipping and replacement options for affected facilities. Healthcare administrators are encouraged to document their response actions and communicate directly with the manufacturer’s recall hotline to ensure complete remediation and prevent future similar events.
Source: FDA Medical Device Recall: Medline Industries Reprocessed Electrophysiology and Ultrasound Catheters
Was this article helpful?
Related Coverage
